VectorBuilder and Lir Advance AI-Driven AAV Capsids

Chicago, Illinois, August 18, 2026

AI-Guided AAV Engineering Targets Multiple Challenges

Under the collaboration, Lir Therapeutics will apply its nAAVigator® artificial intelligence platform and lab-in-the-loop workflow to selected capsids discovered through VectorBuilder’s DeepCap™ platform. Rather than focusing exclusively on developing completely new vectors, the companies plan to optimize capsids that already demonstrate promising biological characteristics. The joint approach is intended to improve several important characteristics simultaneously, including manufacturing productivity, process robustness, full capsid yield and product quality. The companies will also investigate whether optimized capsids can potentially reduce therapeutic dosing requirements while improving tissue specificity and limiting off-target delivery and immune recognition. This integrated strategy reflects a growing role for AI and computational protein engineering in viral vector development. However, the partners emphasize that computational design will be combined with experimental validation and manufacturing assessment. This laboratory feedback is intended to help refine AI-generated designs based on real-world biological and production performance. For gene therapy developers, such an approach could be important because capsid performance involves multiple interconnected characteristics. A vector that performs well in a laboratory model may not necessarily deliver the same advantages when produced at commercial scale or evaluated in a clinical development environment.

Manufacturing Considerations Built Into Capsid Development

One of the central objectives of the collaboration is to address AAV manufacturability during vector engineering rather than after biological optimization. According to the companies, improvements in tissue targeting or potency can sometimes be accompanied by compromises in manufacturing yield, product quality or dosing. VectorBuilder contributes capabilities spanning AAV discovery, capsid engineering, process development and GMP manufacturing, allowing promising candidates to be evaluated from both biological and production perspectives. Lir contributes its AI-based optimization system, creating an iterative development cycle that combines computational design, laboratory testing and manufacturing evaluation. The companies intend to initially assess multiple lead capsids across selected therapeutic applications. Data generated through these studies will be used to guide further optimization of VectorBuilder’s capsid portfolio and may create additional opportunities for therapeutic development partnerships. The collaboration therefore represents an effort to move toward a more comprehensive model of viral vector engineering, in which biological activity, manufacturability, scalability and clinical translation are considered together.

Advancing the Clinical Translation of Gene Therapy

AAV vectors are widely used as delivery vehicles in gene therapy research and development, but challenges involving high doses, off-target effects, pre-existing immunity and manufacturing scalability remain important considerations for the field. VectorBuilder and Lir Therapeutics aim to address several of these challenges through AI-assisted capsid engineering and experimental validation. Dr. Bruce Lahn, Chief Scientist at VectorBuilder, said the goal is to develop capsids that can progress beyond laboratory performance and ultimately reach patients. Lir Therapeutics CEO Killian Hanlon similarly highlighted the company’s focus on using AI to address dose reduction, tissue targeting and immune evasion. The partners believe that combining AI-driven viral vector design with gene delivery expertise and GMP manufacturing capabilities could support development of more practical AAV candidates for future therapeutic programs. While the collaboration is currently focused on optimization and development rather than clinical efficacy results, the work could contribute to the broader effort to improve the efficiency and translational potential of gene therapy platforms. For the gene therapy industry, the partnership highlights an increasingly important development trend: AI is being integrated into the design and optimization of biological medicines, while manufacturing and regulatory considerations are being incorporated earlier in product development. VectorBuilder and Lir’s collaboration aims to apply this integrated approach to AAV capsids and support the progression of promising vectors toward clinical applications.

Source: VectorBuilder, Lir Therapeutics press relese